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Little is known about the mechanisms of anti-inflammatory 
activity of retinoids. A new synthetic vitamin A-like com-
pound (polyprenoic acid derivative, E-5166) has a strong 
in vitro binding affinity to intracellular binding proteins 
for acidic retinoids . In order to elucidate the anti-inflam-
matory activity ofE-5166, we studied the effect ofE-5166 
on the epidermal growth factor (EGF)-stimulated arachi-
donic acid (A A) release of pig epidermis . E-5166 signifi-
V itamin A and its synthetic analogs (retinoids) have been shown to control cellular differentiation and proliferation in many tissues [1]. Besides the inhi-bition of cell proliferation, the effects of retinoids in cystic acne and psoriasis have been attributed to their 
anti-inflammatory action [2,3]. It has been postulated that the 
anti-inflammatory ac tivity might be due to inhibition of the pro-
duction of arachidonic acid (AA)-derived mediators of inflam-
mation, but there are few reports dealing with the abi lity of 
retinoids to inhibit AA metabolism [4]. 
A new synthetic vitamin A-like compound (3,7,11, 15-tetra-
methyl-2,4,6, 10, 14-hexadecapentaenoic acid, E-5166), which was 
originally described by Muto et al [5,6], had a strong in vitro 
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Abbreviations: 
AA: arachidonic acid 
A23187: ionophore A23187 
BSA: bovine serum albumin 
DG: diglycero l 
EGF: epidermal growth factor 
E-5156: 3,7, 11, 15-tetrameth yl-2,4,6, 1 0, 14-hexadecapentaenoic acid 
HC: hydrocortisone 
KRB : Krebs-Ringer buffer 
PA: phosphatidic acid 
PC: phosphatidylcholine 
PE: phosphatidylethanolamine 
PI: phosphatidylinositol 
PLase A2: phospholipase A2 
PS: phosphatidylserine 
TPA: 12-0-tetradecanoylphorbol-13-acetate 
can dy inhibited the EGF-stimulated AA release and this 
inhibitory effect of E-5166 required a longer incubation 
than hydrocortisone did . Furthermore, E-5166 inhibited 
the EGF-stimulated phosphatidylinositol (PI) turnover of 
pig epidermis. These results indicate that E-5166 inhibited 
the EGF-stimulated AA release through the inhibition of 
the EGF-stimulated PI turnover. J Invest Dermatol 88:630-
633, 1987 
binding affinity to intracellular binding proteins for acidic reti-
noids. In order to elucidate the anti-inflammatory action of E-
5166, we studied the effect of E-51 66 ·on the AA metabolism 
particularly the phospholipid-breakdown sys tem of pig epider~ 
mis. As we have already reported that epidermal growth factor 
(EGF) and other phospholipase Az (PLase A z) stimulators in-
creased the AA release from membrane phospholipids of pig ep-
idermis [7], we studied the effect ofE-5166 on the EGF-stimulated 
AA release of pig epidermis. 
In this paper, we report that E-5166 significa ntly inhibited the 
EGF-stimulated AA release and this inhibitory effect of E-5166 
required a longer incubation than HC did. Furthermore, we dis-
cuss different mechanisms of action of E-5166 and HC on the 
inhibition of the AA release in pig epidermis . 
MATERIALS AND METHODS 
Skin sli ces were taken from the backs of domestic pigs, weighing 
6-8 kg, by a Castro viejo keratome set at 0.2 mm depth. As skin 
slices thus obtained contain mainly epidermis (80-90% ), they are 
called epidermal slices [8]. During procedure, pigs were anesthe-
tized with Nembutal (20-30 mg/kg) i. p. Epidermal slices kept in 
RPMI 1640 medium at 4°C were then cut into 5 X 10 mm and 
used within 30 min. 
Epidermal slices were pretreated with or without E-5166 or 
hydrocorti sone (HC) for indicated periods, and then prelabeled 
with [J-I 4CJarachidonic acid W'CJAA) (0 .1 /LCi/ml) for 4 h in 
RPMI 1640 medium with 2% bovine serum albumin (BSA) at 
37°C in a high-humidity incubator in a mixture of 5% COz in 
alL 
After prclabeling, ep idermal slices were washed twice in Ca + + _ 
free RPMI 1640 med ium with 1 mM ethyleneglycoltetraacetic 
acid , and then incubated with or without EGF or other test drugs 
in Ca + + -free RPMI 1640 with 1.2 mM Ca;- + and 2% BSA at 
37°C for 20 min . The incubation was term.inated by removing 
samples from the medium immediately. The radioactivity of 
['4C]AA released in the medium was determined as previously 
0022-202X/87/S03.50 Copyright © 1987 by The Society for In vestigative Dermatology, Inc. 
630 
VOL. 88. NO . MA Y I 'IR7 
described 17 1. In this ex periment sys tcm , we did no t detect any 
sign ifica nt di ffe rencc of I.IC -labcled AA meta bo lites rcieascd in 
the rTIed ium betwcen contro l and E-5 166 t lTat ment. T he AA 
con te n t in the med iulll w as m o re tlu n 85% of th e to tal ac ti vit y. 
Fo r t he stud y of phos pho li pid brea kdown, epiderm al sli ces 
pretreated w ith o r w ith out E- 5 166 fo r 22 h were preiabci ed w ith 
[3H ]g lycero l (2 JLC i/ ml ) fo r J h and then in cubated w ith o r w ith-
o u t EGF fo r indi ca ted perio ds. T he in cubation med iul11 was the 
mod ified Krebs-r~ in ge r buffe r (10 m) w ith HE I'ES (20 m M, pH 
7.4) in t he prese nce of l. 2 m M Ca+ +. T he sa mpl es were rinsed 
in a c hil led KRB and immediatciy frozen between 2 dry- icc pl ates 
to te rrnin ate the reacti on. 
T h e sa mples were thm ho m ogeni zed w ith a g la ss ho m ogenize r 
in 3 ml of chl o ro fo rm :meth ano l (2 :1 ) o r methano l at 4°C. After 
homogeni zat ion , I ml of 2 M KC I. so lutio n was added and the 
uppe r p hase was rcm ovcd . The ex tract was eva po rated to a small 
volum e w ith ni t rogen gas. Lipids and phospho lipids labeled w ith 
[3H ]g l ycero l w ere dissolved in chl o rofor m and analyzcd by thin-
laye r c hro m atog raph y (precoa ted Sili ca Gci G Pl atc, Wako C hem-
ica ls, Osaka , j apan) as described by Sn yder 19 1. The so lvcnt sys-
tem con ta in cd chl o rofo rm: methano b ceti c ac id :H 20 (50 :25 :8:4) 
for p h os pho li pids and li g rain c:eth ano b ceti c acid (50:50: 1) fo r lip-
ids . Each spo t o f lipids and phospho lipids was scraped and its 
rad ioact ivity was de termin ed b y a scin till ati o n co unter . 
For t h e study of IJHlinosito l in co rporati on into phos phati-
dyli nos i tol (PI ), a lo ng in cubatio n sys tcm was empl oyed . E pi-
dermal s li ces pretrea ted w ith o r w itho ut E-5166 fo r 22 h were 
washed tw ice and then in cubated w ith o r w itho ut EG F in the 
prese n ce of rJH li nosito l ( I JLC i/ ml) fo r '1 h. T he in cubatio n m e-
diu m was KR.B w ith H E PES (20 111 M, pH 7.4) in the prescnce 
of Ca -I- + (1.2 m M) . The sa mp les were ho m ogenized and phos-
pholipid frac ti on was extracted . The radioacti vity of an aliq uot 
of p h ospho li pid fractio n labeled w ith IJHlinos ito l was determin ed 
by a scintillation counter as described prev iously [1 01. 
Prote in content was meas ured by the m eth od of Low ry et al 
[11 ]. 
T h e fo llowin g chemi ca ls and drugs we re o btain ed fro lll the 
indica t ed so urces: IJH Ig lycero l, 13H]in os ito l, and 114C] AA (Amer-
sham J a pan , Tokyo, j apan); EG F (Co llaborati ve Resea rch Inc., 
Wa ltb arn , Massac hu setts); lo no pho re A23 187 (A23 187) (Ca lbi-
och e m-Behrin ger Co., Sa n D iego, Ca li fo rn ia); H C, 12- 0 - tetra-
deca n oy lpho lbol-1 3- ace tate (TP A), phos phatid ylethano lamin e 
(PE) , ph osphatidylcho li ne (PC), phosphatid ylserine (PS), and .BSA 
(essen tia l fa tty acid-free) (S ig m a C hel1lical Co. , St. Louis, Mis-
souri); a n d RPMI1 640 and Ca +l -ti'ee RPM I1 640 med ia (G I.B CO, 
Gra n d l shnd , N ew Yo rk). E- 51 66 was a generolls g ift o f Eisa i 
Co., L t d . , Tokyo, j J pan . All other chemi cals and dru gs were 
analy ti c reagcnt g rade. 
RES ULTS 
As sh own in Ta ble I, E-5 '166 at "100 JL M had no detectabl e effect 
on th e A A release stimulated by either A23187, EG F, o r TPA , 
Table I. Effect ofE- 5 :1 66 o n the AA Helcase Stimulated by 
A23187, EG F, and T PA 
None 
A23187 ( 10 /LM) 
EG F (0 .1 /L g/ ml) 
TPA (1 /-LM) 
Tota l in corpo rat ion 
AA Hcleasc (dpm / m g pro tcin / 20 min) 
Contro l 
175 :t 12.9 
500 ± 34.7 
243 ± 1. 1 
277 ± 5.0 
4,250 ± 174.0 
E-5 166 (100 /LM) 
160 ± 2.7 
455 ± 50. 1 
244 ± 2.6 
254 ± 3.6 
4,29 1 ± 37.3 
Epidermal s lices prcl abcled w ith I "ClAA (0. 1 /LC i/ llIl ) we re in cub ated wi th o r 
wi thout E-5 166 ( 100 /L M) in ,he presence o r absence o{ A23 187 (10 /L M). EGF (0. 1 
/Lg/m l). o r T I' A ( I /L M) {or 20 min . T he a mo unt o q " C IAA released in the m edium 
was d e termined and expressed as dp m / m g pro tein ± SEM. N umber of sa 'np lcs = 
3. T o ta l in co rporatioll of 11-1C IA A illto cp id cr l1l :d slices \V:lS dctc rlllill t.'d and ex-
pressed 3 S dpm / m g protein ± SEM . 
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Table II. E ffect of E-51 66 on the AA Helease Stimul ated by 
A23187, EG F, and T PA 
AA Release (d pm/ mg protein/20 m in) 
N onc 
A23 187 (10 /LM) 
EG F (0. 1 /Lg/ ml ) 
T I'A ( I/LM) 
Tota l incorpo rat ion 
Contro l 
255 ± 25.0 
682 ± 7 1. 8 
455 ± 30.4 
486 ± 49.4 
5,284 ± 425 
E-5166 (100 /LM) 
199 ± 18.6 
460 ± 74.8 
236 ± 3 1. 7" 
303 ± 3 1 (i' 
5.077 ± 343 
Epider m al sli ces p rcl abek d w ith o r wi tho ut E-5 166 (100 /LM) {o r 22 hr were 
in cubated w ith I"ClAA (0. 1 /LC i/ ml), and then incu ba ted w ith o r w itho ut A23 187 
( IC) /L M). EGF (0 . 1 /Lg/ ml). and T I' A ( I /L M) for 20 m in . T he am o unt of I "ClAA 
rck ascd ill rh e med iulli WJS de termi ned :l1ld exp ressed as dpm / lll g protcill / 20 mi n 
± SEM . Total in co rpora tion of I "ClAA into epider m al s lices was d ete n ni ned and 
e'p rcssed as dp m / m g protein ± SEM . N um ber of sa 111 pies = 6. 
"1' < 0.0 1 (co m pared w ith contro l). 
1,1' < 0.025 (CO llI pared w ith contro l). 
w hen it was simu ltaneously added to the incubation m edium w ith 
PLase A2 stimula to rs . 
When epidermal sli ces were pretrea ted w ith E-5166 at 100 JL M 
fo r 22 h , it signifi cantly inhibited the AA release stimulated by 
EGF as shown in Ta ble II. The T PA-stimulated AA release was 
also inhibited by th e pretrea tm ent w ith E-5166, but the A23 187-
stimulated one was no t. A prelabelin g fo r 4 h w ith [ '4C] AA 
resu lted in almost the sa m e am ount of I.IC incorporation in to to tal 
phospho lipids o f the control o r E-5166-treated epiderm al sli ces. 
As sho wn in Fig I , E-5166 required at leas t 6 h to inhibit th e 
EG F-st imulated AA release. E-5166 at 100 JLM induced 60% in-
hibition o f the EG F-stil11ulated AA release b y 22-h pretrea tm ent. 
Fi gure 2 shows a dose-dependent stud y of E-5166 effect. E-
5166 at less than 10 JLM had no effect, but 100 JL M and 1 111 M of 
E-5 166 inhibited the EG F-stimulated AA release . 
As shown in Fig 3, the addition of cycloheximide at 1 JLg/ml , 
an inhibi to r of pro tein synthesis, partiall y el iminated the E-5166-
dependent inhibito ry effect o f the EG F-stil11ulated AA release. 
As shown in Fig 4, H C alo ne at 1 JLM o r E-5 166 alo ne at 100 
JLM sig nifi cantl y inhibited the EG F-stil11ulated AA release . T he 
presence o f H C additi vci y po tentiated the inhib itory effect of E-
5166 on the EGF-stimu lated AA release. H ydrocortisone at 10 
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Figure 1. Eficct of E-5166 on the EG F-stimulated AA release (time course 
s tud y). E piderma l sli ces pretreated w ith or w ithout E-5 166 (100 /LM) fo r 
indica ted periods were prclabclcd w ith 1 '4q AA (0. 1 /LC i/ ml) for 4 h, and 
then incubated with EGF at O. I p.g/ ml fo r 20 min . T he amount of l '4qAA 
released in the medium was de termined and expressed as % of 0 time 
va lue. Each b" ,. represents the standard erro r of 3 sa m ples. 
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Figure 2. Effect of E-5166 on the EGF-stimubted AA release (dose stud y). 
Epidermal sli ces pretreated w ith o r w itho ut E-5166 at va rio us concen-
trations fo r 22 h were prelabekd w ith 1'4QA A (0. 1 p,C i/ ml ) fo r 4 h , and 
then incubated w ith or without EGF at 0. 1 p,g/ ml for 20 min. T he alllo unt 
of 1'4C IA A released in the medium was dete rmined and ex pressed as 
dpill / Ill g prote in :t SEM . Number of sa mples = 3; 01' £'11 circles, control ; 
solid cil'cles, EGF 0. 1 p,g/ml. 
J-L M also inhibited the ECF-stimu lated AA release (55.7 ± 5.5%) 
and the inhibi t ion was enhan ced by E-5 166 trea tm ent to 77.3 ± 
2.0% (n = 3). In o rder to furth er elu cidate the act ion mechanism 
of E-5166, the effect o f phospholipid-breakdown sys tem was 
studi ed. In tota l, in 6 separate experiments the form ati o n of 
[3H] g lycero l- labeled di g lycerol (DC) was stimulated by EC F at 
5 min to 333 ± 49% of th e levels of DC at 0 time. As shown in 
Fi g 5, tran sient in crease of [3Hl g lycero l- labeled ] C fo rmation 
stimul ated by ECF was co mpletely inhibited by pretrea tm ent 
with E-51 66 . In this prelabelin g sys tem w ith 13Hl g lycero l for 1 
h , E- 5166 sli ghtl y inhibited r3H] g lycero l labelin g of DC, w hil e 
[3H] g lycero l labelin g o f PA and PI p lus PS was stimul ated by 
pretreatment w ith E-5 166 (data not shown). 
As shown in Table Ill , the formation of 131--1linosito l-labeled PI 
was also stud ied in a continuous labeling sys tem . E pidermal g rowth 
factor stimu lated the fo rmati on of [3H lin osito l-Iabeled PI, w hile 
pretrea tm ent with E-5 166 inhibited th e ECF-stimulated PI for-
mati on. In this sys tem , E-5166 en han ced th e formation o f 
13H]in os itol labe li ng o f PI. 
100 
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Figure 3. E ffect o f cycloheximide and /o r E-5 166 on the EC F-stilllubted 
AA release. Epiderma l sli ces pretrea ted w ith o r w ithout E-5 166 ( 100 p,M) 
in the presence o r absence of cyclo hex imide (1 p,g/ m l) for 22 h were 
pre labeled w ith 1'4CJAA (0. I p,C i/ ml ) fo r 4 h, and then in cubated w ith 
EG F at 0. 1 p,g/m l for 20 min. T he amoun t of r'''C IA A released in the 
medium was determined and ex pressed as dpm / mg protein /20 min ± 
SEM . Number of sa mples = 3. *: I' < 0.0 1 (compared with NO li e). 
Con tro l, shaded arcas; EGF, Opel/ areas. 
T HE JOU I1NAL OF INVESTIGATIVE DEI1MATOLOGY 
PRETREATMENTor-----------------1Too~----__________ ~200 
None 
Hydrocortisone I-________ ~.r • • 
(lpM) 
E·5166 (IDOI'M) 1-------,. •• 
Hydrocortisone .JI •• b 
+ 
E·5166 
Figure 4. E ffect of H C and /o r E-5 '166 on the EGF-stimulated AA release. 
Epiderma l sli ces pret rea ted w ith o r w ithout E-5 1()6 (100 p,M) ill the pres-
ence o r absence o f H C ( I p,M) fo r 22 h we re prelabelcd with 1'4C]AA 
(0.1 p,C i/ ml ), and then incubated w ith ECF (0. I p,g/ ml) for 20 111in. The 
amount of l' 4CJAA released ill the medium was determined and expressed 
as dpm/ mg protei n 20 min ± SEM . *a: I' < 0.001 (compared to NO li e). 
** b: I' < 0.01 (co mpared w ith I-lydrocortisOllc o r E-5·166). 
D ISCUSSION 
Like aro11latic retinoids, E-5166 is clinica ll y effe cti ve, no t only 
for hypcrprolifcrative and dyske rato ti c sk in diseases but also for 
inflammato ry skin di seases such as psori as is vu lga ris and pustula r 
pso ri asis . Althou gh it has bcen postulated that the anti-inflam-
m atory act ivity mi ght be du e to an inhibi tion of the production 
of AA-deriv ed m edi ato rs o f infl am m at io n, Ruzicka [12] failed to 
dem o nstrate th e inhibitor y activity o f aromatic retin o id (RoIO-
1670) on cither lipo xygena sc o r cyclooxygcnase activ ities. Fur-
ther , retinoids have becn shown to both in crease l1 3 J and decrease 
14], or not to affect 114] pros taglandin E2 sy nthes is depending 
upon th e type of cells, the retinoid , and its concen tration. E-51 66 
shares a number of bio logic and ph armacolog ic activities w ith 
aro11latic [etin o ids, but it was not clear how E-51 66 works on 
inflammato ry processes . 
We have previous ly reported that ECF stimulated the release 
o f AA thro ug h the activation of PLase A2 o f pi g epidermis [7]. 
T hc generation of free AA from m embrane phospholipids b y 
PLase A2, w hi ch leads to th e fo rm ation of AA m etabolites, is 
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Figure 5. Effect o f E-5 166 on the EC F-stimulatcd ["H Jg l yce ro l-labeled 
DG fo rmation. Epidermal sli ces pretrea ted with (8) o r witho ut (A) E -
5 166 (100 p,M) for 22 h were prelabeled w ith IJHlg lyce ro l (2 p,C i/ ml) for 
1 h , and then in cubated w ith o r without EC F (0. 1 p,g/ ml ) for 10 min . 
Thc amount of IJHlg lyce ro l-iabcled DC was determ ined and expressed 
as dpm/ mg protein ± SEM fo llowin g thin - layer chro matog raphy analysis 
of li pids ext racted from epidermal hOlll ogenates. Number of sa mples = 
4; "pell circles, contro l; so lid circles, ECF (0. '1 p,g/ ml ). 
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Table III. Effect of E-5166 on the EGF-Stimu lated 
[2H]lnosito l In co rporation into PI 
None 
EGF (0. 1 J.Lg/ llll) 
13H Jlnositol Incorporation 
(dpm/mg protein) 
COlltrol 
1,234 ± 199 
1,76 1 ± 134" 
E-51 66 (100 J.LM) 
1 ,970 ± 303" 
1, ':!65 ± 252" 
Ep ide rmal sli ces prclabclcd w ith or without E-5166 (100 /LM) for 22 h were 
incubated w it h Or w ith o ut EGF (O. I/LS/ml) in the presence of l' H(inos itol ( I/LC i/ ml) 
fo r 1 h. The am o ullt of IJI-Ilinosito l in co rporated in ro PI was derermined and ex-
pressed as dplll / lIl !; protein :!: SEM . Number o f sa mples = 6. 
"p < a.005 (co mpared w ith contro l). 
thought to be a rate-limitin g process . In order to elu cidate the 
mech a nism of ac tion of E-5166 o n the inflammatory processes, 
we s tudied th e effect of E-5166 on the EGF-stil11u latcd AA release 
of pig ep idermis . 
E-5166 significantly inhibited the EGF-stimu lated AA release. 
It required at leas t 6-h in cubation and this inhibitory effect of E-
5166 was parti all y eliminated by the addition of cycloheximide, 
an inhibito r of protein sy nthesis. Furthermore, the presence of 
He a dditively po tentiated the inhibitory effe ct of E-5166 on the 
EGF- stimu lated AA release. 
It has been repo rted that o ne of the important ac tions of co r-
ticosteroids on the inflammatory process is to inhibit PLase A2 
activity by synthetizing an inhibitor protein [15,1 6J. 
As the activation of PLase A2 by EGF was preceded by the 
degradation of PI to DG [10], we were interested in the effect of 
E-5166 on the EGF-stimulated PI turnover. The EGF induced a 
transie nt and sig nifi cant in crease of r3HJ g lycerol-labeled DG for-
ma tion, whi le E -5166 completely inhibited the EGF-stimulated 
DG formation. T he EGF-stimu lated P I form ation was also in-
hibi t e d by E-5166. 
E-5166 failed to inhibit AA re lease stimulated by A23187, which 
activa t es PLase A2 ac tivity witho ut the transient formation of PI 
and P A (17,1 8J. The release of AA by TPA, which activates 
prote in kin ase C directly , w as also inhibited by E-5166, but the 
mech a nism by which TPA stim ul ates AA release is s till unknown. 
These res ults indi cate that E-5166 inhibited the EGF-stimulated 
AA release throug h the inhibition of PI turn over, which is dif-
ferent from the effe ct of HC, although the preci se mechanism of 
action by which E-5166 inhibits PI turnover was not clearly elu-
cidated. 
T h e re are several possible ways in which E-5166 inhibits PI 
turnover stimulated by EGF: (1) E-5166 m ay modulate the EGF 
receptors, (2) E-5166 may inhibit phospholipase C activity, or 
(3) E-5166 m ay inhibit PI resyn thesis. 
In our prelabelin g sys tem, it was observed that E-5166 rather 
inhibited [3HJ g lycerol labeling of DG, while it stimulated 
p H]inositollabeling of PI. In addition , it also stimulated [3HJg lycerol 
labeling of PA and PI plus PS, and [32P] labeling of PA and PI 
pl us PS (data not shown). Sin ce it is reported that retinoids spe-
cifically enhance the number ofEGF recepto rs [19], it is not likely 
tha t E -5166 may modulate them. E-5166 nlay have profound 
effects on phospholipid metabolism of pig epidermis. 
Our prescnt report sugges ts that E-5166 inhibits thc EGF-stim-
ula te d PI brea kdown, the EGF-stimulated AA release, and prob-
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ably the sy nthesis o f AA metabo lites. This inhibitory effect of E-
5166 ma y account for the clinical effectiveness on inflammato ry 
skin di seases . 
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